R
Robert Lim
Researcher at University Health System
Publications - 40
Citations - 5389
Robert Lim is an academic researcher from University Health System. The author has contributed to research in topics: Cancer & Irinotecan. The author has an hindex of 19, co-authored 39 publications receiving 5093 citations. Previous affiliations of Robert Lim include Kyungpook National University Hospital.
Papers
More filters
Journal ArticleDOI
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
Malcolm J. Moore,David Goldstein,John T. Hamm,Arie Figer,J. R. Hecht,Steven Gallinger,Heather J. Au,Pawel Murawa,David Walde,Robert A. Wolff,D. M. B. Campos,Robert Lim,Keyue Ding,Gary M. Clark,Theodora Voskoglou-Nomikos,Mieke Ptasynski,Wendy R. Parulekar +16 more
TL;DR: To the authors' knowledge, this randomized phase III trial is the first to demonstrate statistically significantly improved survival in advanced pancreatic cancer by adding any agent to gemcitabine.
Journal ArticleDOI
Explaining Interindividual Variability of Docetaxel Pharmacokinetics and Pharmacodynamics in Asians Through Phenotyping and Genotyping Strategies
Boon Cher Goh,Soo Chin Lee,Lingzhi Wang,Lu Fan,Jia-Yi Guo,Jatinder K. Lamba,Erin G. Schuetz,Robert Lim,Hong-Liang Lim,Ai-Bee Ong,How Sung Lee +10 more
TL;DR: Midazolam may be used as a probe drug for CYP3A activity to predict docetaxel clearances, hence reducing interindividual variability, and their effects on pharmacokinetics of relevant substrates should be studied further.
Journal ArticleDOI
Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients
Hans-Joachim Schmoll,Thomas H. Cartwright,Josep Tabernero,M. Nowacki,Arie Figer,Jean A. Maroun,Timothy J. Price,Robert Lim,Eric Van Cutsem,Young Suk Park,Joseph McKendrick,Claire Topham,Gemma Soler-Gonzalez,Filipo De Braud,M Hill,Florin Sirzen,Daniel G. Haller +16 more
TL;DR: XELOX has a manageable tolerability profile in the adjuvant setting and Efficacy data will be available within the next 24 months.
Journal ArticleDOI
Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group
Winnie Yeo,Hyun Cheol Chung,Stephen L. Chan,Ling Z. Wang,Robert Lim,Joel Picus,Michael Boyer,Frankie Mo,Jane Koh,Sun Young Rha,Edwin P. Hui,Hei Chul Jeung,Jae Kyung Roh,Simon C.H. Yu,Ka F. To,Qian Tao,Brigette B.Y. Ma,Anthony W.H. Chan,Joanna H.M. Tong,Charles Erlichman,Anthony T.C. Chan,Boon Cher Goh +21 more
TL;DR: Epigenetic therapy with belinostat demonstrates tumor stabilization and is generally well-tolerated and HR23B expression was associated with disease stabilization.
Journal ArticleDOI
Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial
Alfredo Carrato,Anna Swieboda-Sadlej,Marzanna Staszewska-Skurczynska,Robert Lim,Laslo Roman,Yaroslav Shparyk,Igor Bondarenko,Derek J. Jonker,Yan Sun,Jhony A. De la Cruz,J. Andrew Williams,Beata Korytowsky,James G. Christensen,Xun Lin,Jennifer M. Tursi,Maria Jose Lechuga,Eric Van Cutsem +16 more
TL;DR: The study was stopped because of potential futility of sunitinib plus FOLFIRI because of a lack of superiority, and the combination regimen is not recommended for previously untreated mCRC.